The End of Tissue-Type Plasminogen Activator's Reign?

Stroke. 2022 Aug;53(8):2683-2694. doi: 10.1161/STROKEAHA.122.039287. Epub 2022 May 4.

Abstract

Mechanical thrombectomy is a highly effective treatment for acute ischemic stroke caused by large-vessel occlusion in the anterior cerebral circulation, significantly increasing the likelihood of recovery to functional independence. Until recently, whether intravenous thrombolysis before mechanical thrombectomy provided additional benefits to patients with acute ischemic stroke-large-vessel occlusion remained unclear. Given that reperfusion is a key factor for clinical outcome in patients with acute ischemic stroke-large-vessel occlusion and the efficacy of both intravenous thrombolysis and mechanical thrombectomy is time-dependent, achieving complete reperfusion with a single pass should be the primary angiographic goal. However, it remains undetermined whether extending the procedure with additional endovascular attempts or local lytics administration safely leads to higher reperfusion grades and whether there are significant public health and cost implications. Here, we outline the current state of knowledge and research avenues that remain to be explored regarding the consistent therapeutic benefit of intravenous thrombolysis in anterior circulation strokes and the potential place of adjunctive intra-arterial lytics administration, including alternative thrombolytic agent place.

Keywords: bridging therapy; reperfusion; stroke; thrombectomy; thrombolysis.

Publication types

  • Review

MeSH terms

  • Brain Ischemia* / diagnostic imaging
  • Brain Ischemia* / drug therapy
  • Fibrinolytic Agents
  • Humans
  • Ischemic Stroke*
  • Plasminogen / therapeutic use
  • Stroke* / diagnostic imaging
  • Stroke* / drug therapy
  • Thrombectomy / methods
  • Thrombolytic Therapy / methods
  • Tissue Plasminogen Activator
  • Treatment Outcome

Substances

  • Fibrinolytic Agents
  • Plasminogen
  • Tissue Plasminogen Activator